Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Reagan-Udall Foundation Approaches The Starting Line; Next Step Is Funding

Executive Summary

The FDA Amendments Act, which reauthorized the user fee program and gave FDA broad new powers to ensure drug safety, has given the agency an abundance of oversight functions to organize, but also has provided the agency an outside partner: The Reagan-Udall Foundation

You may also be interested in...



FDA Amendments Act’s One-Year Anniversary: For Better Or Worse

At the one-year anniversary of the FDA Amendments Act, the agency's record is mixed in meeting its increased responsibilities and authorities the law requires

FDA Amendments Act’s One-Year Anniversary: For Better Or Worse

At the one-year anniversary of the FDA Amendments Act, the agency's record is mixed in meeting its increased responsibilities and authorities the law requires

FDA’s Pharmacoepidemiology Studies Could Be Funded Through Reagan-Udall

The Reagan-Udall Foundation could fund and select investigators for post-market pharmacoepidemiological studies on behalf of the FDA, a participant at an agency workshop suggested

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS049566

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel